Skip to Main Content
Diseases of the Kidney & Urinary Tract

T1D RELAY

What is the purpose of this trial?

TrialNet is studying the use of rituximab-pvvr and abatacept, one after the other, to learn if using both treatments extends insulin production in people newly diagnosed with type 1 diabetes (T1D).

Previous studies with similar treatments showed people can make more insulin for a longer period of time while receiving either of the treatments. T1D RELAY will study if two treatments consecutively performs better than rituximab-pvvr alone. Researchers will test if those who are also treated with abatacept have better C-peptide levels over time.

  • Trial with
    National Institute of Diabetes and Digestive & Kidney Diseases (NIDDK)
  • Ages
    8 years and older
  • Gender
    Both

Contact Information

For more information about this study, including how to volunteer, contact Marcia DeSousa at The Yale Pediatric Diabetes Program

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    09/04/2024
  • Study HIC
    #2000025525